ArticleBiochemistry2013
Characterization of interactions between heparin/glycosaminoglycan and adeno-associated virus.
Article in Biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 39 citations in OpenAlex.
- Decoding Nonlinearities in AAV-Based Gene Therapy Using PBPK Modelling.The AAPS journal · 2026Article
- Thermodynamics of Binding Between Adeno-Associated Viruses and Heparin in Bulk and at Interfaces via Isothermal Titration Calorimetry.Bioengineering (Basel, Switzerland) · 2026Article
- Surface Plasmon Resonance as a Potential Diagnostic Tool for the Detection of CXC Chemokine Receptor 4 (CXCR4) on Extracellular Vesicles.Biosensors · 2026Article
- Evaluation of transduction efficiency in pancreatic beta and alpha cells utilizing various AAV serotypes.Scientific reports · 2025Article
- Glycan-induced structural activation softens the human papillomavirus capsid for entry through reduction of intercapsomere flexibility.Nature communications · 2024Article
- Re-administration of AAV vectors by masking with host albumin: A Goldilocks hypothesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Adeno-associated virus receptor complexes and implications for adeno-associated virus immune neutralization.Frontiers in microbiology · 2023Article
- Cryo-electron Microscopy of Adeno-associated Virus.Chemical reviews · 2022Review
- Using thermodynamic equilibrium models to predict the effect of antiviral agents on infectivity: Theoretical application to SARS-CoV-2 and other viruses.Microbial risk analysis · 2022Article
- Adeno-associated virus (AAV) cell entry: structural insights.Trends in microbiology · 2022Review
- Enhanced Antiviral Function of Magnesium Chloride-Modified Heparin on a Broad Spectrum of Viruses.International journal of molecular sciences · 2021Article
- Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors.International journal of molecular sciences · 2021Article
- Adeno-Associated Virus (AAV) Gene Delivery: Dissecting Molecular Interactions upon Cell Entry.Viruses · 2021Review
- Investigation of the Differences in Antithrombin to Heparin Binding among Antithrombin Budapest 3, Basel, and Padua Mutations by Biochemical and In Silico Methods.Biomolecules · 2021Article
- Molecular Engineering of Adeno-Associated Virus Capsid Improves Its Therapeutic Gene Transfer in Murine Models of Hemophilia and Retinal Degeneration.Molecular pharmaceutics · 2019Article
- Structure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR.eLife · 2019Article
- Article
- Glycomic and Proteomic Changes in Aging Brain Nigrostriatal Pathway.Molecular & cellular proteomics : MCP · 2018Article
- An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor.Journal of virology · 2018Article
- The 2.8 Å Electron Microscopy Structure of Adeno-Associated Virus-DJ Bound by a Heparinoid Pentasaccharide.Molecular therapy. Methods & clinical development · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Adeno-associated virus (AAV) is a key candidate in the development of gene therapy. In this work, we used surface plasmon resonance spectroscopy to study the interaction between AAV and heparin and other glycosaminoglycans (GAGs). Surface plasmon resonance results revealed that heparin binds to AAV with an extremely high affinity. Solution competition studies showed that binding of AAV to heparin is chain length-dependent. AAV prefers to bind full chain heparin. All sulfo groups (especially N-sulfo and 6-O-sulfo groups) on heparin are important for the AAV-heparin interaction. Higher levels of sulfo group substitution in GAGs enhance their binding affinities. Atomic force microscopy was also performed to image AAV-2 in a complex with heparin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.